Wockhardt Limited has informed the Exchange regarding a press release dated January 13, 2025, titled Zaynich? (Zidebactam/Cefepime, WCK 5222) achieves over 97% Efficacy in Clinical Study for serious infections caused by Meropenem-Resistant Gram-Negative Pathogens .".